Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Aug 18;9(8):e103413.
doi: 10.1371/journal.pone.0103413. eCollection 2014.

The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy

Affiliations

The molecular phenotype of endocapillary proliferation: novel therapeutic targets for IgA nephropathy

Jeffrey B Hodgin et al. PLoS One. .

Abstract

IgA nephropathy (IgAN) is a clinically and pathologically heterogeneous disease. Endocapillary proliferation is associated with higher risk of progressive disease, and clinical studies suggest that corticosteroids mitigate this risk. However, corticosteroids are associated with protean cellular effects and significant toxicity. Furthermore the precise mechanism by which they modulate kidney injury in IgAN is not well delineated. To better understand molecular pathways involved in the development of endocapillary proliferation and to identify novel specific therapeutic targets, we evaluated the glomerular transcriptome of microdissected kidney biopsies from 22 patients with IgAN. Endocapillary proliferation was defined according to the Oxford scoring system independently by 3 nephropathologists. We analyzed mRNA expression using microarrays and identified transcripts differentially expressed in patients with endocapillary proliferation compared to IgAN without endocapillary lesions. Next, we employed both transcription factor analysis and in silico drug screening and confirmed that the endocapillary proliferation transcriptome is significantly enriched with pathways that can be impacted by corticosteroids. With this approach we also identified novel therapeutic targets and bioactive small molecules that may be considered for therapeutic trials for the treatment of IgAN, including resveratrol and hydroquinine. In summary, we have defined the distinct molecular profile of a pathologic phenotype associated with progressive renal insufficiency in IgAN. Exploration of the pathways associated with endocapillary proliferation confirms a molecular basis for the clinical effectiveness of corticosteroids in this subgroup of IgAN, and elucidates new therapeutic strategies for IgAN.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Literature-based analysis from the 424 genes regulated in E1 vs. E0 biopsies using Genomatix Pathway System (GePS) software.
The picture shows the 248 genes that were co-cited in PubMed abstracts in the same sentence with a function-word filter.

References

    1. Bartosik LP, Lajoie G, Sugar L, Cattran DC (2001) Predicting progression in IgA nephropathy. American Journal of Kidney Diseases 38: 728–735. - PubMed
    1. Barratt J, Feehally J (2005) IgA nephropathy. Journal of the American Society of Nephrology 16: 2088–2097. - PubMed
    1. Roberts IS, Cook HT, Troyanov S, Alpers CE, Amore A, et al. (2009) The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney International - PubMed
    1. Cattran DC, Coppo R, Cook HT, Feehally J, Roberts IS, et al. (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney International - PubMed
    1. Herzenberg AM, Fogo AB, Reich HN, Troyanov S, Bavbek N, et al. (2011) Validation of the Oxford classification of IgA nephropathy. Kidney International 80: 310–317. - PubMed

Publication types

Substances

Associated data